FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616667577> ?p ?o ?g. }

• W2616667577 endingPage "8528" @default.
• W2616667577 startingPage "8528" @default.
• W2616667577 abstract "8528 Background: STA-4783 (S), an inducer of heat shock protein 70 (hsp70) is a bis-thiobenzoylhydrazide compound. S leads to up-regulation of hsp70 in tumor cell lines. Xenograft models of solid tumors showed synergistic anti-tumor activity in combination with paclitaxel (P). The combination P + S, in phase I and II studies, showed dose-related hsp70 induction (evidence of biological activity) and tolerability. Methods: Eligibility was based on a diagnosis of metastatic cutaneous melanoma, ECOG <=2, and prior treatment with 1 or no chemotherapy regimens. A total of 81 patients (pts) were randomized 2:1 (P 80 mg/m 2 + S 213 mg/m 2 :P 80 mg/m 2 ) 3 weeks out of 4 at 21 US clinical sites. The primary endpoint was progression free survival (PFS); secondary endpoints were response rate (RR), and adverse events (AEs). Results: Based on intent-to-treat analysis, the median PFS was 3.68 months (m) for P + S vs. 1.84 m in the P only arm (p=.035). RR was 15.1% in the P + S arm and 3.6% in the P arm. Subgroup analysis showed chemo- naive pts (n=23) with P + S showed a median PFS of 8.28 m vs. 2.40 in the P arm (n=9). For pts with 1 prior chemotherapy, (n=29), PFS on P + S was 3.12 m vs. 1.77 m on P (n=19). Of 19 pts who crossed over at progression, data are available for 14. PFS ranged from 0.72 to 5.5 m. Three of the 14 evaluable pts treated with P alone had rapid progression (0.95, 1.6, and 1.7 m) then significant inversion of the time to progression with the addition of S to P (2.3, 5.5, and 4.2 m) suggesting study drug effect. Scans were done at identical intervals (8 weeks). The proportion of pts with AEs of grade 3 or higher was 54% (n=52) in the P + S group and 57% in the P group (n=28); pts on P received a median of 2 cycles, while pts in the P + S group received a median of 4. Adverse events leading to discontinuation were low in both groups: 10% for the P + S, and 14% for P. Conclusions: The addition of S to P showed an increase in PFS vs. P alone particularly in chemo-naïve pts. A few pts failing single agent P appeared to benefit from P + S. Despite the additional treatment duration in the P + S group the drugs were well- tolerated, and showed mainly P related adverse events. A phase III study is planned to confirm a role for P + S in metastatic melanoma. [Table: see text]" @default.
• W2616667577 created "2017-05-26" @default.
• W2616667577 creator A5002655892 @default.
• W2616667577 creator A5005836279 @default.
• W2616667577 creator A5038290045 @default.
• W2616667577 creator A5052564588 @default.
• W2616667577 creator A5056670989 @default.
• W2616667577 creator A5060495866 @default.
• W2616667577 creator A5067317372 @default.
• W2616667577 creator A5073111231 @default.
• W2616667577 creator A5080450234 @default.
• W2616667577 creator A5081765963 @default.
• W2616667577 date "2007-06-20" @default.
• W2616667577 modified "2023-09-25" @default.
• W2616667577 title "Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma" @default.
• W2616667577 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.8528" @default.
• W2616667577 hasPublicationYear "2007" @default.
• W2616667577 type Work @default.
• W2616667577 sameAs 2616667577 @default.
• W2616667577 citedByCount "9" @default.
• W2616667577 countsByYear W26166675772020 @default.
• W2616667577 crossrefType "journal-article" @default.
• W2616667577 hasAuthorship W2616667577A5002655892 @default.
• W2616667577 hasAuthorship W2616667577A5005836279 @default.
• W2616667577 hasAuthorship W2616667577A5038290045 @default.
• W2616667577 hasAuthorship W2616667577A5052564588 @default.
• W2616667577 hasAuthorship W2616667577A5056670989 @default.
• W2616667577 hasAuthorship W2616667577A5060495866 @default.
• W2616667577 hasAuthorship W2616667577A5067317372 @default.
• W2616667577 hasAuthorship W2616667577A5073111231 @default.
• W2616667577 hasAuthorship W2616667577A5080450234 @default.
• W2616667577 hasAuthorship W2616667577A5081765963 @default.
• W2616667577 hasConcept C126322002 @default.
• W2616667577 hasConcept C141071460 @default.
• W2616667577 hasConcept C143998085 @default.
• W2616667577 hasConcept C168563851 @default.
• W2616667577 hasConcept C187960798 @default.
• W2616667577 hasConcept C197934379 @default.
• W2616667577 hasConcept C203092338 @default.
• W2616667577 hasConcept C2776694085 @default.
• W2616667577 hasConcept C2777292972 @default.
• W2616667577 hasConcept C2777658100 @default.
• W2616667577 hasConcept C2778375690 @default.
• W2616667577 hasConcept C2780739268 @default.
• W2616667577 hasConcept C31760486 @default.
• W2616667577 hasConcept C44249647 @default.
• W2616667577 hasConcept C502942594 @default.
• W2616667577 hasConcept C71924100 @default.
• W2616667577 hasConcept C90924648 @default.
• W2616667577 hasConceptScore W2616667577C126322002 @default.
• W2616667577 hasConceptScore W2616667577C141071460 @default.
• W2616667577 hasConceptScore W2616667577C143998085 @default.
• W2616667577 hasConceptScore W2616667577C168563851 @default.
• W2616667577 hasConceptScore W2616667577C187960798 @default.
• W2616667577 hasConceptScore W2616667577C197934379 @default.
• W2616667577 hasConceptScore W2616667577C203092338 @default.
• W2616667577 hasConceptScore W2616667577C2776694085 @default.
• W2616667577 hasConceptScore W2616667577C2777292972 @default.
• W2616667577 hasConceptScore W2616667577C2777658100 @default.
• W2616667577 hasConceptScore W2616667577C2778375690 @default.
• W2616667577 hasConceptScore W2616667577C2780739268 @default.
• W2616667577 hasConceptScore W2616667577C31760486 @default.
• W2616667577 hasConceptScore W2616667577C44249647 @default.
• W2616667577 hasConceptScore W2616667577C502942594 @default.
• W2616667577 hasConceptScore W2616667577C71924100 @default.
• W2616667577 hasConceptScore W2616667577C90924648 @default.
• W2616667577 hasIssue "18_suppl" @default.
• W2616667577 hasLocation W26166675771 @default.
• W2616667577 hasOpenAccess W2616667577 @default.
• W2616667577 hasPrimaryLocation W26166675771 @default.
• W2616667577 hasRelatedWork W1982967647 @default.
• W2616667577 hasRelatedWork W2075296106 @default.
• W2616667577 hasRelatedWork W2100029565 @default.
• W2616667577 hasRelatedWork W2163003060 @default.
• W2616667577 hasRelatedWork W2300929849 @default.
• W2616667577 hasRelatedWork W2789668336 @default.
• W2616667577 hasRelatedWork W2794755247 @default.
• W2616667577 hasRelatedWork W2801876548 @default.
• W2616667577 hasRelatedWork W3197516152 @default.
• W2616667577 hasRelatedWork W4294192809 @default.
• W2616667577 hasVolume "25" @default.
• W2616667577 isParatext "false" @default.
• W2616667577 isRetracted "false" @default.
• W2616667577 magId "2616667577" @default.
• W2616667577 workType "article" @default.